Nuvectis Pharma, Inc. (NVCT) Posts 4 Complete Responses in Phase 1b Glioma Study

What happened

Nuvectis reported four complete responses, meaning the tumors disappeared, and tumor shrinkage in 22 of 27 patients in a Phase 1b study of oral NXP200 for BRAF V600-mutated recurrent or progressive gliomas, which are brain tumors.

Confirmed

Global impact / market context

Complete responses in brain tumors are rare, so the result could signal a strong drug profile and draw partnering or takeover interest. Still, this is early Phase 1b data, and larger controlled studies plus durability and survival data are needed before any major re-rating.

Analyst inference

The article says NXP200 sits within a validated BRAF class and compares its 40% high-grade response rate favorably to a historical 33% with combo therapy. That supports a possible monotherapy role, but an active U.S. IND filing and confirmatory data remain ahead.

Analyst inference

What to watch

1. The company reported manageable safety: Grade 3 or higher treatment-related side effects occurred in 14.3% of patients, with no discontinuations or deaths, which may ease advancement and the regulatory path. Confirmed
2. A U.S. IND, which is an application to test the drug in U.S. clinical trials, is described as needed; watch whether Nuvectis files it and moves NXP200 into larger controlled studies. Proposed
3. Watch confirmatory durability and survival data: the article's early median duration of response in high-grade patients is a short-term measure, and longer benefit would support valuation, partnering, or takeover interest. Analyst inference

Evidence

• financewire.com